001432957 000__ 05684cam\a2200541\a\4500
001432957 001__ 1432957
001432957 003__ OCoLC
001432957 005__ 20230309003542.0
001432957 006__ m\\\\\o\\d\\\\\\\\
001432957 007__ cr\un\nnnunnun
001432957 008__ 201217s2021\\\\sz\\\\\\o\\\\\000\0\eng\d
001432957 019__ $$a1227389283$$a1228045802$$a1228845119$$a1236895439$$a1237479120
001432957 020__ $$a9783030565145$$q(electronic bk.)
001432957 020__ $$a3030565149$$q(electronic bk.)
001432957 020__ $$z3030565130
001432957 020__ $$z9783030565138
001432957 0247_ $$a10.1007/978-3-030-56514-5$$2doi
001432957 035__ $$aSP(OCoLC)1227240921
001432957 040__ $$aYDX$$beng$$epn$$cYDX$$dN$T$$dOCLCO$$dGW5XE$$dEBLCP$$dUPM$$dOCLCF$$dOCLCO$$dOCLCQ$$dCOM$$dCASUM$$dOCLCQ
001432957 049__ $$aISEA
001432957 050_4 $$aRC632.L5
001432957 08204 $$a616.399706
001432957 24500 $$aTherapeutic lipidology /$$cMichael H. Davidson, Peter P. Toth, Kevin C. Maki, editors.
001432957 250__ $$a2nd ed.
001432957 260__ $$aCham :$$bHumana Press,$$c2021.
001432957 300__ $$a1 online resource
001432957 336__ $$atext$$btxt$$2rdacontent
001432957 337__ $$acomputer$$bc$$2rdamedia
001432957 338__ $$aonline resource$$bcr$$2rdacarrier
001432957 347__ $$atext file
001432957 347__ $$bPDF
001432957 4901_ $$aContemporary Cardiology,$$x2196-8969
001432957 5050_ $$aChapter 1. History of Lipidology -- Chapter 2. Atherogenesis and Vascular Biology -- Chapter 3. Genetic Disorders of Lipoprotein Metabolism -- Chapter 4. Cardiovascular Genomics -- Chapter 5. Epidemiology of Atherosclerotic Cardiovascular Disease -- Chapter 6. Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines -- Chapter 7. The Low-Density Lipoprotein Cholesterol Hypothesis: An Update -- Chapter 8. Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk -- Chapter 9. Medical Nutrition Therapy for Lipid and Lipoprotein Disorders -- Chapter 10. Nutraceuticals and Lipid Management -- Chapter 11. Pharmacology of Statins -- Chapter 12. Management of Statin Intolerance -- Chapter 13. Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins and Plant Sterols -- Chapter 14. Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and its Therapeutic Inhibition -- Chapter 15. Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids) -- Chapter 16. Pathophysiology and Management of Dyslipidemias Associated with Insulin-resistant States -- Chapter 17. Therapeutic Management of Obesity -- Chapter 18. High Density Lipoproteins -- Chapter 19. Lipoprotein (a): Principles from Bench to Bedside -- Chapter 20. Management of Homozygous Familial Hypercholesterolemia -- Chapter 21. Lysosomal Acid Lipase Deficiency -- Chapter 22. Lipodystrophies -- Chapter 23. HIV and Dyslipidemia -- Chapter 24. Cardiovascular Disease in Women: Focus on Lipid Management -- Chapter 25. Management of Dyslipidemia in the Elderly -- Chapter 26. Management of Dyslipidemia in Children -- Chapter 27. Lipoprotein Subfractions in Clinical Practice -- Chapter 28. Ion Mobility Lipoprotein Analysis -- Chapter 29. How ApoB Measurements Could Improve Prevention of Cardiovascular Disease -- Chapter 30. C-reactive Protein and Other Inflammatory Markers in Cardiovascular Disease; Inflammatory Disorders and Atherosclerosis -- Chapter 31. Coronary Artery Calcium and CT Angiography -- Chapter 32. The Clinical Use of Ultrasound for Atherosclerosis Imaging -- Chapter 33. Emerging Therapies for Regulating Dyslipidemias and Atherosclerosis -- Chapter 34. The Allied Health Professional's Role in the Management of Dyslipidemia and Accreditation Council for Clinical Lipidology Certification Program -- Chapter 35. The American Board of Clinical Lipidology Physician Certification Program.
001432957 506__ $$aAccess limited to authorized users.
001432957 520__ $$aThe second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease. The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related to atherosclerosis and cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
001432957 650_0 $$aLipids$$xMetabolism$$xDisorders$$xTreatment.
001432957 655_0 $$aElectronic books.
001432957 7001_ $$aDavidson, Michael,$$d1956-$$eeditor.
001432957 7001_ $$aToth, Peter P.,$$eeditor.
001432957 7001_ $$aMaki, Kevin C.,$$eeditor.
001432957 77608 $$iPrint version:$$z3030565130$$z9783030565138$$w(OCoLC)1164494601
001432957 830_0 $$aContemporary cardiology (Totowa, N.J.),$$x2196-8969
001432957 852__ $$bebk
001432957 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-56514-5$$zOnline Access$$91397441.1
001432957 909CO $$ooai:library.usi.edu:1432957$$pGLOBAL_SET
001432957 980__ $$aBIB
001432957 980__ $$aEBOOK
001432957 982__ $$aEbook
001432957 983__ $$aOnline
001432957 994__ $$a92$$bISE